Zachary S Zumsteg1,2, Benjamin H Lok3, Allen S Ho2,4, Esther Drill5, Zhigang Zhang5, Nadeem Riaz3, Stephen L Shiao1,2, Jennifer Ma3, Sean M McBride3, C Jillian Tsai3, Shrujal S Baxi6, Eric J Sherman6, Nancy Y Lee3. 1. Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California. 2. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California. 5. Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Despite controversy surrounding its benefit, the use of concomitant chemoradiotherapy (CCRT) in patients with oropharyngeal squamous cell carcinoma (OPSCC) who are aged > 70 years is increasing. However, to the authors' knowledge, few studies to date have compared the outcomes of different systemic treatments in this population. METHODS: Records from 74 patients aged ≥ 70 years with stage III to stage IVB OPSCC who were undergoing CCRT from 2002 to 2013 at a single institution were reviewed. Patients were stratified according to the systemic therapy received, including cisplatin, carboplatin with either 5-fluorouracil or paclitaxel (CARB), or cetuximab to compare oncologic outcome and toxicity. RESULTS: The median follow-up was 36 months. The median age of the patients was 75.3 years (range, 70-91 years), with significantly older patients receiving cetuximab (P = .03). A total of 28, 20, and 26 patients, respectively, received CCRT with cisplatin, CARB, and cetuximab. RT interruptions of > 1 day were needed in 4% of patients receiving cisplatin, 20% of patients receiving CARB, and 15% of patients receiving cetuximab (P = .19). Unplanned hospitalizations during CCRT occurred in 25%, 55%, and 58%, respectively, of patients receiving cisplatin, CARB, and cetuximab (P = .03). There were 2 treatment-related deaths, both of which occurred among the patients who were treated with cetuximab. At 5 years, locoregional control was achieved in 100%, 88%, and 60% (P<.001), respectively, and the overall survival rate was 87%, 61%, and 47% (P = .03), respectively, among patients treated with cisplatin, CARB, and cetuximab. CONCLUSIONS: Toxicity from CCRT remains a challenge for older adults with OPSCC. Herein, the authors found no evidence that this toxicity was mitigated by treatment with cetuximab. Nevertheless, a subset of patients aged ≥70 years appear to tolerate cisplatin-based treatment with acceptable toxicity and excellent outcomes. Further identification of this patient subgroup is crucial to optimize therapy for older patients with OPSCC. Cancer 2017;123:1345-1353.
BACKGROUND: Despite controversy surrounding its benefit, the use of concomitant chemoradiotherapy (CCRT) in patients with oropharyngeal squamous cell carcinoma (OPSCC) who are aged > 70 years is increasing. However, to the authors' knowledge, few studies to date have compared the outcomes of different systemic treatments in this population. METHODS: Records from 74 patients aged ≥ 70 years with stage III to stage IVB OPSCC who were undergoing CCRT from 2002 to 2013 at a single institution were reviewed. Patients were stratified according to the systemic therapy received, including cisplatin, carboplatin with either 5-fluorouracil or paclitaxel (CARB), or cetuximab to compare oncologic outcome and toxicity. RESULTS: The median follow-up was 36 months. The median age of the patients was 75.3 years (range, 70-91 years), with significantly older patients receiving cetuximab (P = .03). A total of 28, 20, and 26 patients, respectively, received CCRT with cisplatin, CARB, and cetuximab. RT interruptions of > 1 day were needed in 4% of patients receiving cisplatin, 20% of patients receiving CARB, and 15% of patients receiving cetuximab (P = .19). Unplanned hospitalizations during CCRT occurred in 25%, 55%, and 58%, respectively, of patients receiving cisplatin, CARB, and cetuximab (P = .03). There were 2 treatment-related deaths, both of which occurred among the patients who were treated with cetuximab. At 5 years, locoregional control was achieved in 100%, 88%, and 60% (P<.001), respectively, and the overall survival rate was 87%, 61%, and 47% (P = .03), respectively, among patients treated with cisplatin, CARB, and cetuximab. CONCLUSIONS:Toxicity from CCRT remains a challenge for older adults with OPSCC. Herein, the authors found no evidence that this toxicity was mitigated by treatment with cetuximab. Nevertheless, a subset of patients aged ≥70 years appear to tolerate cisplatin-based treatment with acceptable toxicity and excellent outcomes. Further identification of this patient subgroup is crucial to optimize therapy for older patients with OPSCC. Cancer 2017;123:1345-1353.
Authors: Stephanie A Michal; David J Adelstein; Lisa A Rybicki; Cristina P Rodriguez; Jerrold P Saxton; Benjamin G Wood; Joseph Scharpf; Denise I Ives Journal: Head Neck Date: 2011-10-22 Impact factor: 3.147
Authors: Caitriona B O'Neill; Shrujal S Baxi; Coral L Atoria; James P O'Neill; Martin C Henman; Eric J Sherman; Nancy Y Lee; David G Pfister; Elena B Elkin Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Sheela Hanasoge; Kelly R Magliocca; Jeffrey M Switchenko; Nabil F Saba; J Trad Wadsworth; Mark W El-Deiry; Dong M Shin; Fadlo Khuri; Jonathan J Beitler; Kristin A Higgins Journal: Head Neck Date: 2015-07-30 Impact factor: 3.147
Authors: Megan E Daly; Derick H Lau; D Gregory Farwell; Quang Luu; Paul J Donald; Allen M Chen Journal: Am J Otolaryngol Date: 2013-08-15 Impact factor: 1.808
Authors: Jeremy Setton; Nicola Caria; Jonathan Romanyshyn; Lawrence Koutcher; Suzanne L Wolden; Michael J Zelefsky; Nicholas Rowan; Eric J Sherman; Matthew G Fury; David G Pfister; Richard J Wong; Jatin P Shah; Dennis H Kraus; Weiji Shi; Zhigang Zhang; Karen D Schupak; Daphna Y Gelblum; Shyam D Rao; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-16 Impact factor: 7.038
Authors: Arya Amini; Bernard L Jones; Jessica D McDermott; Hilary S Serracino; Antonio Jimeno; David Raben; Debashis Ghosh; Daniel W Bowles; Sana D Karam Journal: Cancer Date: 2016-03-11 Impact factor: 6.860
Authors: Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison Journal: J Clin Oncol Date: 2014-12-08 Impact factor: 44.544
Authors: Martin Steinau; Mona Saraiya; Marc T Goodman; Edward S Peters; Meg Watson; Jennifer L Cleveland; Charles F Lynch; Edward J Wilkinson; Brenda Y Hernandez; Glen Copeland; Maria S Saber; Claudia Hopenhayn; Youjie Huang; Wendy Cozen; Christopher Lyu; Elizabeth R Unger Journal: Emerg Infect Dis Date: 2014-05 Impact factor: 6.883
Authors: Rama R Damerla; Nancy Y Lee; Daoqui You; Rekha Soni; Rachna Shah; Marsha Reyngold; Nora Katabi; Vanessa Wu; Sean M McBride; Chiaojung Jillian Tsai; Nadeem Riaz; Simon N Powell; N Esther Babady; Agnes Viale; Daniel S Higginson Journal: JCO Precis Oncol Date: 2019-04-03
Authors: Salman A Eraj; Mona K Jomaa; Crosby D Rock; Abdallah S R Mohamed; Blaine D Smith; Joshua B Smith; Theodora Browne; Luke C Cooksey; Bowman Williams; Brandi Temple; Kathryn E Preston; Jeremy M Aymard; Neil D Gross; Randal S Weber; Amy C Hessel; Renata Ferrarotto; Jack Phan; Erich M Sturgis; Ehab Y Hanna; Steven J Frank; William H Morrison; Ryan P Goepfert; Stephen Y Lai; David I Rosenthal; Tito R Mendoza; Charles S Cleeland; Kate A Hutcheson; Clifton D Fuller; Adam S Garden; G Brandon Gunn Journal: Radiat Oncol Date: 2017-09-09 Impact factor: 3.481